In a melanoma mouse model, the addition of adjuvant chemotherapy after ablative RT abrogated the RT-induced CD8+ T cell activation and tumor control, while the addition of immunotherapy can enhance the tumor response (98), suggesting that the treatment modalities and the sequence of their combination need to be carefully investigated to achieve clinical success. The gene discussed is CD8A; the disease is neoplasm.